Differences in baseline surgical risk and the evolution of optimal medical therapy confound direct comparisons between older (STICH) and contemporary (REVIVED-BCIS2) revascularization trials in ischemic cardiomyopathy.
Marquis-Gravel et al. (Thu,) studied this question.